Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line
- PDF / 5,315,062 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 98 Downloads / 143 Views
SYSTEMATIC REVIEW
Efficacy and Safety of Bevacizumab Plus Oxaliplatin‑ or Irinotecan‑Based Doublet Backbone Chemotherapy as the First‑Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta‑analysis Tianshu Ren1,2 · Shu Wang1 · Zexu Shen1 · Chang Xu1 · Yingshi Zhang1 · Fuhai Hui1 · Xingshun Qi3 · Qingchun Zhao1,2 Accepted: 2 September 2020 © Springer Nature Switzerland AG 2020
Abstract Introduction and Objective Guidelines recommend combined doublet backbone chemotherapy based on 5-fluorouracil and oxaliplatin (OX) or irinotecan (IR) as the first-line treatment options for metastatic colorectal cancer. However, it is still unknown which is better when combined with bevacizumab (BEV). This systematic review and meta-analysis were performed to compare BEV-IR with BEV-OX regimens in terms of efficacy and safety. Methods We searched studies from databases including MEDLINE, EMBASE, CENTRAL, and conference papers. The outcomes were overall response rate, overall survival, progression-free survival, and the incidence of the most common adverse events. The dichotomous data were reported as the risk ratio (RR) and the survival outcomes were extracted as the hazard ratio with 95% confidence interval (CI). Results Eleven studies including 5632 patients were identified. No difference was found in overall survival or overall response rate between BEV-IR and BEV-OX regimens. The pooled progression-free survival was significantly longer in the BEV-IR group than the BEV-OX group (hazard ratio = 0.92, 95% CI 0.87–0.98, p = 0.08). Compared with the BEV-OX group, the BEV-IR group was related to a higher risk of bleeding events (RR = 0.80, 95% CI 0.64–0.98, p = 0.03), venous thromboembolism (RR = 0.60, 95% CI 0.46–0.79, p = 0.0002), and diarrhea (RR = 0.71, 95% CI 0.62–0.80, p
Data Loading...
